SARS-CoV-2 Receptor Binding Domain IgG Response to AstraZeneca (AZD1222) COVID-19 Vaccination, Jamaica
| Autor: | Ynolde E Leys, Gavin Cloherty, Jerome P Walker, Magdalene Nwokocha, Velesha Frater, Tamara Thompson, Mark S. Anderson, Tiffany R Butterfield, Joshua J. Anzinger |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
education.field_of_study
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Population Vaccination Antibody response Injection site pain Internal medicine Medicine Chills Symptom onset medicine.symptom business education |
| DOI: | 10.1101/2021.10.22.21265401 |
| Popis: | The Caribbean region is lacking an assessment of the antibody response and side effects experienced after AstraZeneca COVID-19 vaccination (AZD1222). We examined SARS-CoV-2 spike receptor binding domain (RBD) IgG levels and reported side effects in a Jamaican population after AZD1222 vaccination. Median RBD IgG levels for persons without evidence of previous SARS-CoV-2 infection were 43.1 bIU/mL after 3-7 weeks post first dose, rising to 100.1 bIU/mL 3-7 weeks post second dose, and falling 46.9 bIU/mL 16-22 weeks post second dose. The median RBD IgG level 2-8 weeks after symptom onset for unvaccinated SARS-CoV-2 infected persons of all disease severities was 411.6 bIU/mL. Common AZD1222 side effects after first dose were injection site pain, headache and chills. Most persons reported no side effects after second dose. AZD1222 is widely used across the English-speaking Caribbean and the study provides evidence for its continued safe and effective use in vaccination programs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|